Design and development of spirulina polysaccharide-loaded nanoemulsions with improved the antitumor effects of paclitaxel / Manling Du, Zhenjiang Yang, Wenping Lu, Bingyue Wang, Qi Wang, Zhen Chen, Lianyu Chen, Shuyan Han, Tiange Cai, Yu Cai
Abstract Aims: In this study, we prepared spirulina polysaccharides into spirulina polysaccharide-loaded nanoemulsions (SPS-NEs), and determined the antitumor effect of SPS-NEs, when combined with paclitaxel (PTX). Methods: SPS-NEs were prepared by a phase transformation method. The Characterisation and stability of SPS-NEs was measured. The antitumor effect of SPS-NEs combined with PTX was determined by S180 cells or RAW 264.7 macrophages and S180 tumour-bearing mice. Results: SPS-NEs were spherical and stable, the particle size of SPS-NEs was 84.6 ± 3.31 nm, PDI = 0.235 ± 0.02. PTX + SPS-NEs exhibited a much greater toxicity against RAW 264.7 cells than PTX. PTX + SPS-NEs increased the release of NO, IL-6 and TNF-α, and the expression of p-p65 NF-κB, p-I-κB, TLR4. In addition, PTX + SPS-NEs significantly inhibited tumour growth by 72.82% and increased the secretion of serum IL-2, TNF-α and IFN-γ. Conclusions: SPS-NEs can regulate immunity through TLR4/NF-κB signalling pathways, which enhances the anti-tumour effect of PTX.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Journal of microencapsulation - 37(2020), 6, Seite 403-412 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Du, Manling [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Themen: |
Nanoemulsions |
|---|
| Umfang: |
1 Online-Ressource (10 p) |
|---|
| doi: |
10.1080/02652048.2020.1767224 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL011204168 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011204168 | ||
| 003 | DE-627 | ||
| 005 | 20231109210046.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230714s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/02652048.2020.1767224 |2 doi | |
| 035 | |a (DE-627)KFL011204168 | ||
| 035 | |a (KFL)prod_LgpH_10.1080/02652048.2020.1767224 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Du, Manling |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Design and development of spirulina polysaccharide-loaded nanoemulsions with improved the antitumor effects of paclitaxel |c Manling Du, Zhenjiang Yang, Wenping Lu, Bingyue Wang, Qi Wang, Zhen Chen, Lianyu Chen, Shuyan Han, Tiange Cai, Yu Cai |
| 264 | 1 | |c 2020 | |
| 300 | |a 1 Online-Ressource (10 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Aims: In this study, we prepared spirulina polysaccharides into spirulina polysaccharide-loaded nanoemulsions (SPS-NEs), and determined the antitumor effect of SPS-NEs, when combined with paclitaxel (PTX). Methods: SPS-NEs were prepared by a phase transformation method. The Characterisation and stability of SPS-NEs was measured. The antitumor effect of SPS-NEs combined with PTX was determined by S180 cells or RAW 264.7 macrophages and S180 tumour-bearing mice. Results: SPS-NEs were spherical and stable, the particle size of SPS-NEs was 84.6 ± 3.31 nm, PDI = 0.235 ± 0.02. PTX + SPS-NEs exhibited a much greater toxicity against RAW 264.7 cells than PTX. PTX + SPS-NEs increased the release of NO, IL-6 and TNF-α, and the expression of p-p65 NF-κB, p-I-κB, TLR4. In addition, PTX + SPS-NEs significantly inhibited tumour growth by 72.82% and increased the secretion of serum IL-2, TNF-α and IFN-γ. Conclusions: SPS-NEs can regulate immunity through TLR4/NF-κB signalling pathways, which enhances the anti-tumour effect of PTX | ||
| 653 | |a Spirulina polysaccharide | ||
| 653 | |a nanoemulsions | ||
| 653 | |a paclitaxel | ||
| 653 | |a tumour | ||
| 653 | |a TLR4/NF-κB signalling pathway | ||
| 700 | 1 | |a Yang, Zhenjiang |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Wenping |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Bingyue |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Zhen |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Lianyu |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Shuyan |e verfasserin |4 aut | |
| 700 | 1 | |a Cai, Tiange |e verfasserin |4 aut | |
| 700 | 1 | |a Cai, Yu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of microencapsulation |d Abingdon : Taylor & Francis Group, 1984 |g 37(2020), 6, Seite 403-412 |h Online-Ressource |w (DE-627)KFL000005967 |w (DE-600)1491079-2 |w (DE-576)079719244 |x 1464-5246 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2020 |g number:6 |g pages:403-412 |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/tandf-ejournals-pharmazie/doi.org/10.1080/02652048.2020.1767224 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-TFE | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_LgpH_02 | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2020 |e 6 |h 403-412 | ||